About Us

Gregory Oakes

President & Chief Executive Officer

Greg is an accomplished pharmaceutical executive bringing more than 25 years of experience to Landos. He most recently served as Executive Vice President & President, North America at Vifor Pharma where he was an Executive Committee member.  Previously, Greg held leadership positions of increasing responsibility at Amgen, Celgene, Novartis, and Schering-Plough. He has a proven track record of advancing clinical stage programs through successful commercialization. Greg also has extensive experience in strategy, business development, sales and marketing, pricing, access and reimbursement, strategic partnerships and driving top and bottom-line growth for small, mid-sized and large pharmaceutical companies.

Greg received his BS from PennWest Edinboro and his MBA from Clemson University.

Close

Chris Garabedian

Chairman

Chris Garabedian is founder and CEO of Xontogeny, a biotech aggregator that supports life science technologies from early development through clinical proof of concept. He also established the firm’s venture fund strategy in a partnership with Perceptive Advisors. Prior to joining Xontogeny, he served as the President and CEO of Sarepta Therapeutics, overseeing the development of the company’s Duchenne muscular dystrophy program. His previous positions also include VP of Corporate Strategy at Celgene and various global leadership roles at Gilead. Currently, Garabedian serves on the Board of Directors of MassBio, the Keck Graduate Institute, and is a Senior Advisor for the Boston Consulting Group.

Close

Roger Adsett

Chief Operating Office of Insmed, Inc.

Roger Adsett is currently the Chief Operating Officer of Insmed, Inc., a commercial stage biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Roger has almost 30 years of experience in commercial leadership and operations for global life science companies across multiple therapeutic areas and geographies. Roger brings with him a proven record of successfully building businesses in rare diseases, specialty and primary care, launching both blockbuster and specialty brands. Prior to his current role at Insmed, Mr. Adsett served as the company’s Chief Commercial Officer. Before joining Insmed, he worked 11 years at Shire, where he was SVP of GI & Internal Medicine. Mr Adsett joined Shire after 11 years at AstraZeneca.

Close

Alka Batycky, PH.D.

Director

Dr. Batycky is an accomplished biopharmaceutical executive and brings over 25 years of global drug development expertise in the biopharmaceutical industry, spanning from early discovery through product approval across multiple therapeutic modalities including small molecules, biologics and combination products. She has broad experience across a range of therapeutic areas including ulcerative colitis, Crohn’s disease, rheumatoid arthritis, asthma, as well as other inflammation disorders. Dr. Batycky’s expansive skill set includes corporate and portfolio strategy, business and corporate development, regulatory affairs and research and development. Most recently, Dr. Batycky served as Chief Development Officer at Finch Therapeutics. Prior to this, she held executive leadership positions at various biopharmaceutical companies including Ohana Biosciences, Akashi Therapeutics, Warp Drive Bio and AMAG Pharmaceuticals. She also has held positions of increasing responsibility at CombinatoRx, Synta Pharmaceuticals, Alkermes and GSK.

Dr. Batycky received her undergraduate and doctoral degrees in toxicology and pharmacology at the School of Pharmacy, University of London, and conducted post-doctoral research at the Medical Research Council, Leicester, UK.

Close

Fred Callori

Xontogeny, Perceptive Advisors

Since September 2017, Mr. Callori has served as Senior Vice President, Corporate Development at Xontogeny, LLC, a life sciences accelerator. Mr. Callori also serves as a partner in the Perceptive Xontogeny Venture Funds, a position he has held since December 2019. Prior to Xontogeny and Perceptive, from 1998 to August 2017, Mr. Callori was a partner in the Life Science and Emerging Companies practices of Choate, Hall & Stewart LLP. Mr. Callori holds a J.D. from Boston University School of Law and a B.A. in Economics from Binghamton University.

Close

Tiago Girão

CFO of Proteovant Therapeutics

Tiago Girão is currently the Chief Financial Officer of ProteoVant Therapeutics, a newly launched development-stage biotech company created by Roivant Sciences that focuses on the discovery and development of disease-modifying therapies by harnessing natural protein homeostasis processes. Mr. Girão has more than 20 years of experience in accounting, finance, and operations for U.S. and global private and public life sciences companies. Previously, Mr. Girão was the CFO and SVP of Operations at Cytori Therapeutics (NASDAQ: PSTV) from September 2014 to March 2019. Before that, he served as International Controller at NuVasive (NASDAQ: NUVA) from April 2012 to August 2014. Earlier in his career, Mr. Girão served as Senior Manager, Assurance at KPMG in the U.S. from October 2004 to March 2012, as well as Ernst & Young in Brazil from October 2000 to August 2004. Mr. Girão will bring valuable insight as a cross-functional leader to Landos, as he has conducted successful capital raising strategies and executed productive business development initiatives.

Close

Tim M. Mayleben

Director

Tim M. Mayleben most recently served as Landos Biopharma’s Interim President & CEO. Prior to Landos, Tim served as the President, CEO and Director of Esperion Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of therapies for the treatment of patients with elevated levels of LDL-cholesterol. In this role, he oversaw the development, strategy and commercial product launch of NexletolTM/NexlizetTM, as well as initiated collaborations with key commercial and development partners. Mr. Mayleben has more than two decades of executive leadership experience in the life science industry including as former President, CEO and Director of Vericel Corporation (formerly Aastrom Biosciences, Inc.), former President, COO and Board member of Virtual Radiologics (formerly Nighthawk Radiology Holdings, Inc), and former COO and CFO of the original Esperion Therapeutics, Inc. until its acquisition by Pfizer, Inc. (NYSE: PFE) in 2004. Mr. Mayleben also serves as an Independent Board member of Marinus Pharmaceuticals (NASDAQ: MRNS) and Kaleo, Inc. where he also serves as non-executive Chairman.

Mr. Mayleben earned an M.B.A., with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.B.A. from the University of Michigan, Ross School of Business.

Close

Jean-Frederic Colombel, MD

Icahn School of Medicine at Mount Sinai

New York, United States

Close

Geert D’Haens, MD, PhD

Amsterdam UMC, University of Amsterdam

Amsterdam, The Netherlands

Close

Silvio Danese, MD, PhD

IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University

Milan, Italy

Close

Marla Dubinsky, MD

Icahn School of Medicine at Mount Sinai

New York, United States

Close

Brian G. Feagan, MD, FRCPC

Western University

London, Ontario, Canada

Close

Remo Panaccione, MD, FRCPC

University of Calgary

Calgary, Canada

Close

Laurent Peyrin-Biroulet, MD, PhD

Nancy University Hospital, University of Lorraine

Vandoeuvre-lès-Nancy, France

Close

Florian Reider, MD

Cleveland Clinic

Cleveland, United States

Close

Stefan Schreiber, MD

UKSH-Campus Kiel

Kiel, Germany

Close

Britta Siegmund, MD, PhD

Charité – Universitätsmedizin, Berlin

Berlin, Germany

Close

Bram Verstockt, MD, PhD

University Hospitals Leuven, KU Leuven

Leuven, Belgium

Close

Andres Yarur, MD

Cedars Sinai Medical Center

Los Angeles, United States

Close